At a glance
- Originator GlaxoSmithKline
- Class Peptides
- Mechanism of Action Neuropeptide Y receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 21 Nov 2001 Preclinical development for Obesity in USA (unspecified route)